LabCentral

LabCentral Joins ARPA-H Investor Catalyst Hub Spoke Network

Retrieved on: 
Monday, March 25, 2024
Health, Organization, Development, Patient, Research, Ecosystem, LabCentral, ARPA, DARPA, Pharmaceutical industry

CAMBRIDGE, Mass., March 25, 2024 /PRNewswire/ -- LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, today announced that it is now a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.

Key Points: 
  • Based in the Greater Boston area and managed by VentureWell , the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions.
  • "Our spoke network embodies a rich and representative range of perspectives and expertise," said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub.
  • As an Investor Catalyst Hub spoke, LabCentral gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts.
  • The spoke network will continue to grow as The Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis.

LabCentral and Astellas Launch Inaugural $500,000 "Diamond Ticket" at LabCentral 238

Retrieved on: 
Tuesday, March 5, 2024
Diamond, Regenerative medicine, Biotechnology, Research, LabCentral, Investment, Golden Ticket, Kendall Square, Patient, Heart, Science, Pharmaceutical industry

NORTHBROOK, Ill. and CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, and Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced the LabCentral 238 Diamond Ticket award. The Diamond Ticket is the largest lab space award of its kind in the industry and provides an innovative, growth-stage biotech company with a $500,000 credit for private lab space at LabCentral 238, one of the newest facilities in the LabCentral network in the heart of Kendall Square. Interested companies can review program details and apply online before the April 5, 2024 deadline.

Key Points: 
  • Astellas' support is a key part of its commitment to discovering and advancing innovative science.
  • "LabCentral 238 has expanded the options for growth-stage biotechs that need more space and specialized biomanufacturing equipment, enabling them to "grow" inside the LabCentral network of facilities and remain in Kendall Square," said Johannes Fruehauf, co-founder and president of LabCentral.
  • "From the beginning, Astellas has been much more than a founding sponsor; they have been a true partner.
  • A select number of entrepreneurs will be invited to present virtually to a joint selection committee made up of representatives from LabCentral and Astellas in April 2024.

EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update

Retrieved on: 
Thursday, December 14, 2023
Growth, Bridge, Drug discovery, Evotec, EVO, Novo Nordisk, Mass General Brigham, Biomarker, ISIN, Research, Frankfurt Stock Exchange, MDAX, Creative Biolabs, Yale University, Harvard University, EBITDA, MBC, Match point, LabCentral, Pharmaceutical industry, Arms industry, Fine chemical, Silviculture

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.
  • Costs of € 43.9 m were incurred in 2023 as a direct result of the cyber-incident in early April, including additional external expenditures and internal recovery contributions.
  • In response to the criminal cyber-attack, Evotec took immediate action to contain and remediate the attack by taking its external-facing systems offline.
  • This was deemed necessary to protect all the Company’s partners and stakeholders and meant Evotec could ensure that the integrity of scientific data remained unaffected.

Dr. Benjamin Wolozin to Present "Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology" at CTAD 2023

Retrieved on: 
Tuesday, October 24, 2023
FDA, MIT, Cognition, Vaccine, Neuron, Hope, Takeda, Neurology, LabCentral, Pathology, Boston Park Plaza, Entrepreneurship, Research, Protein, Manhattan Center, Brain damage, Anatomy, Pfizer, ALS, Boston University School of Public Health, Killing Floor 2, Tau, AbbVie, Foundation for the National Institutes of Health, Patient, Kendall Square, Neuroscience, Alzheimer's Association, Memory, Pharmaceutical industry, Medical imaging, Alzheimer's disease

CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, today announced that the company's Co-Founder and Chief Scientific Officer, Dr. Benjamin Wolozin MD, Ph.D., will be presenting new preclinical research at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference. CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.

Key Points: 
  • CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.
  • CTAD 23 is sold out, but attendees can still register for virtual attendance.
  • Our therapeutic removes abnormal tau protein, which is the key protein contributing to loss of memory and cognition in Alzheimer's disease.
  • If successful in clinical trials, Aquinnah's treatment offers the hope of reducing the brain damage and correspondingly restoring brain function for patients suffering from Alzheimer's disease."

EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy

Retrieved on: 
Wednesday, September 27, 2023
Partnership, MDAX, Frankfurt Stock Exchange, Medication, Research, Patient, MBC, LabCentral, Drug discovery, ISIN, Ecosystem, Creative Biolabs, Safety, EVO, Fine chemical, Pharmaceutical industry

LabCentral / BioLabs / MBC BioLabs offers laboratory and office spaces for over 400 start-ups comprising approximately 3,500 scientists and entrepreneurs, giving Evotec direct access to promising research of biotech companies across the US, France and Germany.

Key Points: 
  • LabCentral / BioLabs / MBC BioLabs offers laboratory and office spaces for over 400 start-ups comprising approximately 3,500 scientists and entrepreneurs, giving Evotec direct access to promising research of biotech companies across the US, France and Germany.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “The collaboration with LabCentral / BioLabs / MBC BioLabs is closely aligned with our mission ‘Together for Medicines that Matter’.
  • Our goal has always been to empower brilliant entrepreneurs within a thriving ecosystem that fosters innovation, collaboration, and ultimately, success.
  • Evotec’s shared R&D platform dovetails with our shared lab co-working space, furthering this mission.”
    No financial terms of the agreement were disclosed.

NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO's Demo Day

Retrieved on: 
Wednesday, June 7, 2023
Science, technology, engineering, and mathematics, Exhibition, Demo, National Science and Technology Council (Taiwan), Taipei Veterans General Hospital, Taipei Medical University Hospital, Biotechnology, 3D, University, Y, Insteon, Multimedia, Attention, Antibody, Immunotherapy, CDMO, LabCentral, Medicine, Hospital, Ecosystem, NSTC, Video game, Science

The event effectively assisted start-up teams in establishing global exposure and promoting cooperation and exchange between Taiwan's biotech industry and the global market.

Key Points: 
  • The event effectively assisted start-up teams in establishing global exposure and promoting cooperation and exchange between Taiwan's biotech industry and the global market.
  • The Demo Day was held in the form of Demo & Pitch, featuring presentations by 20 teams supported by NSTC.
  • Among them, Taipei Veterans General Hospital, China Medical University Hospital and Show Chwan Memorial Hospital are the teams of NSTC's Smart Healthcare Industry-Academia Consortium Project.
  • JelloX Biotech has developed patented 3D pathology tissue processing and imaging technology to develop next-generation pathology detection technology.

LabCentral Ignite Launches Third Annual Golden Ticket Contest

Retrieved on: 
Monday, May 15, 2023
Amgen, Novartis Institute for Tropical Diseases, First Citizens BancShares, Biomedical Research, Senior, Face, Stroke, Process, Silicon Valley Bank, Cancer, Golden Ticket (The Office), Kendall Square, Bristol Myers Squibb, Nanomedicine, Science, Thought, Interest, Harmony, Silicon, LabCentral, MA, Golden Ticket, Wilson Sonsini Goodrich & Rosati, BMS, B cell, Health, Therapy, Amusement park, Pharmaceutical industry, Creative industries, Film industry, Takeda, Pfizer

CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/ -- LabCentral Ignite, a platform dedicated to advancing racial, gender and other representation and opportunity within the life sciences field, today launched its third annual Golden Ticket contest that is designed to support diverse, underrepresented biotech entrepreneurs who are using innovative science to solve problems for human health. Interested entrepreneurs and scientists can visit LabCentral Ignite Golden Tickets for a program overview, eligibility rules, and to apply.

Key Points: 
  • Interested entrepreneurs and scientists can visit LabCentral Ignite Golden Tickets for a program overview, eligibility rules, and to apply.
  • "Bristol Myers Squibb is delighted to partner with LabCentral for a second year by supporting the LabCentral Ignite Golden Ticket contest," said Emma Lees, Senior Vice President, Oncology Discovery and Site Head for BMS Cambridge R&D.
  • In addition, the inaugural LabCentral Ignite Golden Ticket winners from 2021 each received significant investment last year, including a $6 million seed round for Harmony and a $10 million Series A for Nanopath with a lead investor coming through LabCentral Ignite.
  • A select number of finalists will receive access to coaching and will be invited to present at a pitch event on September 19th where the eight winning companies will be awarded LabCentral Ignite Golden Tickets.

Bayer Opens First Co.Lab Life Science Incubator in Cambridge

Retrieved on: 
Thursday, May 4, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Janus, State, Business development, CGT, Bayer, Kendall Square, MIT, LabCentral, Harvard University, Innovation Center station, Entrepreneurship, BRIC, Economic development, Ecosystem, Labs, Fine chemical, Pharmaceutical industry

Bayer AG announced today the inauguration of its new life science incubator dubbed “Co.Lab Cambridge” located in Kendall Square in Cambridge, U.S. Bayer’s Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies (CGT) entrepreneurs with access to Bayer’s enterprise wide expertise in addition to state-of-the-art laboratory and office space.

Key Points: 
  • Bayer AG announced today the inauguration of its new life science incubator dubbed “Co.Lab Cambridge” located in Kendall Square in Cambridge, U.S. Bayer’s Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies (CGT) entrepreneurs with access to Bayer’s enterprise wide expertise in addition to state-of-the-art laboratory and office space.
  • “The opening of our Co.Lab Cambridge in the same location as the Bayer Research and Innovation Center will create an exceptional interdisciplinary community.
  • “I am thrilled to see this new life science incubator coming to Cambridge and Bayer recognizing our community as the perfect place to harness cutting edge research and entrepreneurship,” said State Senator Sal DiDomenico.
  • “This flagship life science incubator, through the strength and ingenuity of the Bayer company, will forward critical research in the cell and gene therapy space.

ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs

Retrieved on: 
Tuesday, April 18, 2023
Golden Ticket, ONO, Organization, MBC, LabCentral, The Golden Ticket, Neurology, Pharmaceutical industry, Film industry

CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.

Key Points: 
  • CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (ONO), and applications will be received through May 2023.
  • The Golden Ticket awards provide promising early-stage R&D companies lab space and mentorship, two components vital to the success of nascent life science businesses.
  • "As longtime believers in open innovation and the power of partnerships, we are excited once again to offer this Golden Ticket competition in collaboration with LabCentral and MBC BioLabs," said Kunihiko Ito, President and CEO of ONO PHARMA USA.

LabCentral 2022 Impact Report: Companies Raised $6.05 Billion in Funding Including 21% of All Early-Stage Funding Nationwide, Granted 56 Patents and Dosed 4,504 Participants in 37 Clinical Trials

Retrieved on: 
Tuesday, April 11, 2023
Career, Heart, Intellectual property, Kendall Square, Research, Science, Acquisition, Economic development, LabCentral, Series, Growth, Health, Pharmaceutical industry, Video game

CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- LabCentral, the first-of-its-kind network of shared laboratory spaces designed as launchpads for high-potential biotech startups, today announced its annual Impact Report detailing the influence of its 81 resident and 166 alumni companies on the local and national life sciences and biotech industry. The impact was measured in terms of funding, patents, clinical trials, job creation as well as LabCentral's expanded facilities and programs from the past year. The 2022 Impact Report is available on LabCentral's website along with reports from previous years.

Key Points: 
  • The impact was measured in terms of funding, patents, clinical trials, job creation as well as LabCentral's expanded facilities and programs from the past year.
  • Key statistics from the LabCentral 2022 Impact Report include:
    Funding – LabCentral companies have raised a total of $22.95 billion in funding since 2013.
  • In 2022 alone, LabCentral resident and alumni companies secured $6.05 billion in total funding and acquisition proceeds from all sources.
  • Clinical Research – Resident and alumni companies have started 116 clinical trials since 2013, including 37 last year researching unique indications with various technologies.